Reducing Systemic Inflammation in People on Antiretroviral Therapy
Status:
NOT_YET_RECRUITING
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
This randomized, open-label clinical trial will evaluate whether adding fostemsavir to current antiretroviral therapy can reduce the risk of cardiovascular disease in people with well-controlled HIV. Researchers will compare imaging, clinical and biomarker outcomes between participants who receive fostemsavir in addition to their existing treatment and those who continue with standard care alone.
Phase:
PHASE2
Details
Lead Sponsor:
Centre hospitalier de l'Universit de Montral (CHUM)
Collaborators:
BC Women's Hospital & Health Centre Clinique du Quartier Latin McGill University Health Centre/Research Institute of the McGill University Health Centre